DocCode — SEQ. TXT
`
`SCORE Placeholder Sheet for IFW Content
`
`Application Number: 15467648
`
`Document Date: 03/23/2017
`
`The presence of this form in the IFW record indicates that the following document type was received
`in electronic format on the date identified above. This content is stored in the SCORE database.
`
`Since this was an electronic submission, there is no physical artifact folder, no artifact folder is
`recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW
`record were created from the original documents that are stored in SCORE.
`
`Sequence Listing
`
`At the time of document entry (noted above):
`eo
`USPTO employees may access SCORE content via eDAN using the Supplemental Content
`tab, or via the SCORE web page.
`External customers may access SCORE content via PAIR using the Supplemental Content
`tab.
`
`e
`
`Form Revision Date: August 26, 2013
`
`0001
`
`0001
`
`MYLAN - EXHIBIT 1024
`
`

`

`PTO/AIA/15 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`
`
`a
`
`UTI LITY
`
`Attorney Docket No.
`
`SYPA-009/C04US
`
`\
`
`
`
`First Inventor
`
`Stephen COMISKEY
`
`
`
`PATE NT AP P LI CATI Oo N
`
`Title
`
`FORMULATIONS OF GUANYLATE
`CYCLASE C AGONISTS AND METHODS
`
`TRANSMITTAL
`.
`oo
`(Only for new nonprovisional applications under 37 CFR 1.53(b}}
`
`\_
`
`OF USE
`
`Express Mail Label No.
`
`J
`
`
`
`
`
`APPLICATION ELEMENTS
`
`ADDRESS TO:
`
`Commissioner for Patents
`b.0. Box 1450
`
`See MPEP chapter 600 concerning utility patent application contents.
`Alexandria VA 22313-1450
`
`1. [] Fee Transmittal Form
`ACCOMPANYING APPLICATION PARTS
`(PTO/SB/17 or equivalent)
`2. X Applicant asserts small entity status.
`See 37 CFR 1.27.
`
`10. [] Assignment Papers
`(cover sheet & document(s))
`
`
`
`11.
`
`Name of Assignee
`
`
`
`
`
`37 CFR 3.73(c) Statement
`(when there is an assignee)
`
`[] Power of Attorney
`
`English Translation Document
`(if applicable)
`
`Information Disclosure Statement
`(PTO/SB/08 or PTO-1449)
`
`Copies of citations attached
`Preliminary Amendment
`
`Return Receipt Postcard
`(MPEP § 503) (Should be specifically itemized)
`
`Certified Copy of Priority Document(s)
`(if foreign priority is claimed)
`
`Nonpublication Request
`Under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form
`PTO/SB/35 or equivalent.
`
`Other:
`
`OO Ooo ogo
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18
`
`3. [] Applicant certifies micro entity status. See 37 CFR 1.29.
`Applicant must attach form PTO/SB/15A or B or equivalent.
`4. X Specification
`[Total Pages 148
`|
`Both the claims and abstract must start on a new page.
`(See MPEP § 608.01(a) for information on the preferred arrangement)
`5. X Drawing(s). {35 U.S.C. 113)
`[Total Sheets
`_6
`|
`6. Inventor's Oath or Declaration
`[Total Sheets
`_8
`|
`(including substitute statements under 37 CFR 1.64 and assignments
`serving as an oath or declaration under 37 CFR 1.63(e))
`
`a. [] Newly executed (original or copy)
`
`b. X A copy from a prior application (37 CFR 1.63(d})
`
`7. X Application Data Sheet ~~ *See Note below.
`See 37 CFR 1.76 (PTO/AIA/14 or equivalent)
`
`8. [] CD-ROM or CD-R
`in duplicate, large table or Computer Program (Appendix)
`
`[] Landscape Table on CD
`9. Nucleotide and/or Amino Acid Sequence Submission
`(if applicable, items a. — c. are required)
`
`a.
`
`Computer Readable Form (CRF)
`
`b. [] Specification Sequence Listing on:
`
`i. [] CD-ROM or CD-R (2 copies); or
`
`ii. [] Paper
`
`C. [] Statements verifying identity of above copies
`
`
`
`
`
`
`*Note:
`
`(1) Benefit claims under 37 CFR 1.78 and foreign priority claims under 1.55 must be included in an Application Data Sheet (ADS).
`(2) For applications filed under 35 U.S.C. 111, the application must contain an ADS specifying the applicant if the applicant is an
`assignee, person to whom the inventor is under an obligation to assign, or person who otherwise shows sufficient proprietary
`interest in the matter. See 37 CFR 1.46(b).
`
`
`
`19. CORRESPONDENCE ADDRESS
`
`
`
`X The address associated with Customer Number: __ 58249
`
`
`OR [] Correspondence address below
`
`
`
`Name
`
`
`
`Address
`
`
`
`
`
`
`
`City
`State
`Zip Code
`
`
`Country
`Telephone
`Email
`(signature
`/Anne E. Fleckenstein/
`| Date
`[March 23, 2017
`)
`| (orm /rype)
`Anne E. Fleckenstein
`orogeny | 62,951
`J
`
`
`
`
`
`
`This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO
`to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on
`the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND
`TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`If you need assistance in completing the form, call 1-800-PT0O-9199 and select option 2.
`| American Legal diz [e)
`
`RS
`win
`www. FormsWork
`
`
`143328891 v1
`
`
`
`0002
`
`

`

`
`Electronic Patent Application Fee Transmittal
`
`
`Application Number:
`
`
`Filing Date:
`
`
`Title of Invention:
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF
`USE
`
`
`
`First Named Inventor/Applicant Name:
`Stephen COMISKEY
`
`
` SYPA-009C04US 321994-
`
`Anne Elizabeth Fleckenstein
`Filer:
`
`
`Attorney Docket Number:
`
`
`Filed as Small Entity
`
`
`Filing Fees for
`
`Utility under 35 USC 111(a)
`
`
`
`
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`ont) in
`
`Basic Filing:
`
`
`
`UTILITY FILING FEE (ELECTRONIC FILING)
`4011
`1
`70
`70
`
`
`
`
`
`
`
`
`Pages:
`
`
`
`UTILITY APPL SIZE FEE PER 50 SHEETS >100
`2081
`1
`200
`200
`
`
`
`
`Claims:
`
`
`
`Miscellaneous-Filing:
`
`
`
`
`
`
`
`UTILITY SEARCH FEE
`
`UTILITY EXAMINATION FEE
`
`2111
`
`2311
`
`1
`
`1
`
`300
`
`360
`
`300
`
`360
`
`
`
` Petition: 0003
`
`0003
`
`

`

`
`
`
`
`Description
`
`
`
`Fee Code
`
`Quantity
`
`
`
`
`
`Amount
`
`Sub-Total in
`USD($)
`
`
`
`Patent-Appeals-and-Interference:
`
`
`
`Post-Allowance-and-Post-Issuance:
`
`
`
`Extension-of-Time:
`
`
`
`
`
`
`
`Miscellaneous:
`
`Total in USD ($)
`
`930
`
`
`
`0004
`
`0004
`
`

`

`
`
`Electronic Acknowledgement Receipt
`
`
`
`EFS ID:
`
`28715614
`
`
`
`Application Number:
`
`15467648
`
`
`
`International Application Number:
`
`
`
`Confirmation Number:
`
`2133
`
`
`
`Title of Invention:
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF
`USE
`
`
`
`First Named Inventor/Applicant Name:
`
`Stephen COMISKEY
`
`
`
`Customer Number:
`
`58249
`
`
`
`Filer:
`
`Anne Elizabeth Fleckenstein
`
`
`
`Filer Authorized By:
`
`
`
`Attorney Docket Number:
`
`SYPA-009C04US 321994-
`
`
`
`Receipt Date:
`
`23-MAR-2017
`
`
`
`Filing Date:
`
`
`
`Time Stamp:
`
`16:29:33
`
`
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`
`
`Payment information:
`
`
`
`Submitted with Payment
`
`yes
`
`
`
`
`
`
` The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Payment Type
`
`DA
`
`
`
`Payment was successfully received in RAM
`
`$930
`
`
`
`RAM confirmation Number
`
`032417INTEFSW00016915501283
`
`
`
`Deposit Account
`
`
`
`Authorized User
`
`
`
`0005
`
`0005
`
`

`

`
`
`
`
`File Listing:
`
`
`
`Document
`Number
`
`eo.
`Document Description
`
`.
`File Name
`
`Multi
`File Size(Bytes)/
`.
`.
`Message Digest | Part /.zip|
`
`Pages
`.
`(if appl.)
`
`
`
`1793952
`
`1
`
`
`
`Application Data Sheet
`
`SYPA_009_C04US_ADS.pdf
`
`
`
`
`
`
`7e8e69fa21de76bc43fdcabfcf0847806774
`
`028c
`
`no
`
`10
`
`
`
`
`
`Warnings:
`
`
`
`Information:
`
`
`
`5
`
`SYPA_009_C04u5 Application.
`
`818629
`
`
`yes
`
`148
`
`
`
`
`
`p
`
`7a318e564c5a1e9b53035dc48ab32263¢77]
`
`9ebBc
`
`
`
`
`
`Multipart Description/PDF files in .zip description
`
`
`
`Document Description
`
`Start
`
`End
`
`
`
`Specification
`
`1
`
`145
`
`
`
`146
`
`147
`
`
`
`Claims
`
`Abstract
`
`148
`
`148
`
`
`
`
`
`
`
`
`
`
`Warnings:
`
`
`
`Information:
`
`
`
`3
`
`Drawings-only black and white line
`drawi
`
`rawi ng S
`
`SYPA_009_C04US_Drawings.
`df
`
`478132
`
`
`no
`
`6
`
`p
`
`f49c0e28d03942783023adbafa98ff46666e
`
`
`
`Warnings:
`
`
`
`
`
`
`
`
`
`
`Information:
`
`4
`
`Oath or Declaration filed
`
`SYPA009_C0445. Declaration.
`
`931375
`
`no
`
`8
`
`p
`
`926p57d2ab04c16243e8f3b89a92c40520e|
`
`2c48f
`
`
`
`Warnings:
`
`
`
`Information:
`
`230955
`
`
`5
`
` 0qo6
`a4ed90c32fd1b78810b7f0a9335e37256892
`
`
`Transmittal of New Application
`
`SYPA_009_C04US Transmittal.
`pdf
`
`
`
`no
`
`1
`
`
`
`0006
`
`

`

`
`
`Warnings:
`
`
`
`Information:
`
`
`
`115883
`
`
`
`
`
`
`6
`
`Sequence Listing (Text File)
`
`
`
`
`
`SYPA_009_ COALS _Seqlist 512
`
`no
`
`-
`
`Warnings:
`
`Information:
`
`
`
`
`
`
`
`
`
`
`
`7
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`36884
`
`d57bad77c534e7cd2c24e9209c60ec393c5
`
`6d937
`
`
`
`Warnings:
`
`
`
`Information:
`
`
`
`
`
`Total Files Size (in bytes):
`
`4405810
`
`
`
` This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`
`
`New Applications Under 35 U.S.C. 111
`If
`a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`
`
`New International Application Filed with the USPTO as a Receiving Office
`If
`a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`
`
`
`
`0007
`
`0007
`
`

`

`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`}
`}
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`
`
`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`
`
`
`
`
`
`Secrecy Order 37 CFR 5.2:
`
`
`
`[7 Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`
`
`Inventor Information:
`
`
`
`
`
`Inventor
`
`Legal Name
`
`[1
`
`Remove
`
`
`
`
`
`Suffix
`
`|
`
`
`
`
`
`
`
`Prefix| Given Name
`|
`Itephen
`
`Middle Name
`
`Family Name
`COMISKEY
`
`
`
`
`
`
`
`
`
`
`Non US Residency
`Active US Military Service
`e
`US Residency
`Residence Information (Select One)
`
`Country of Residencé |
`State/Province | PA
`City
`| Poylestown
`lS
`
`
`
`
`
`
`
` Mailing Address of Inventor:
`
`
`
`Address 1
`
`05 Steeplechase Drive
`
`Address 2
`
`
`
`
`
`
`City
`
`| Doylestown
`
`
`State/Province
`
`| PA
`
`
`Country
`
`| us
`
`
`
`Postal Code
`
`18902
`
`
`
`
`
`
`
`
`
`Remove
`
`[2
`Inventor
`
`Legal Name
`
`
`
`Prefix| Given Name
`+]
`Rong
`
`Middle Name
`
`
`
`
`
`Residence Information (Select One) (8) US Residency
`
`Family Name
`FENG
`
`
`Non US Residency
`
`Active US Military Service
`
`
`
`Suffix
`
`|
`
`
`-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Country of Residence | Us
`State/Province | PA
`City | Langhorne
`
`
`
`
`
`
`
` Mailing Address of Inventor:
`
`
`
`Address 1
`
`/4 Pine Glen Road
`
`Address 2
`
`
`
`
`
`
`
`City
`Postal Code
`
`
`
`| anghorne
`
`19047
`
`
`
`
`
`
`
`State/Province
`
`Country
`|
`lus
`
`PA
`
`
`
`
`
`3
`Inventor
`
`Legal Name
`
`
`
`
`
`Middle Name
`
`Suffix
`Family Name
`Prefix| Given Name
`
`+]
`pohn
`FOSS
`|
`
`
`
`
`
`
`
`Active US Military Seryice
`Residence Information (Select One) (®) US Residency
`Non US Residency
` \“AvA~ASS
`
`
`
`
`
`
`
`
`
`
`
`
`
`EFS Web 2.2.12
`
`0008
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1.76
` Application Number
`
`
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`
`Title of Invention
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`State/Province | PA
`| Country of Residencd |
`US
`City | Poylestown
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mailing Address of Inventor:
`
`
`
`Address 1
`h25 Linden Avenue
`
`
`Address 2
`
`City
`| Doylestown
`State/Province
`| PA
`
`
`Postal Code
`18901
`Countryi
`| us
`
`
`
`U4
`Inventor
`
`Legal Name
`
`
`
`Middle Name
`
`
`
`
`
`
`
`
`
`Suffix
`Family Name
`Prefix| Given Name
`
`kunwar
`+]
`SHAILUBHAI
`+]
`
`
`
`
`
`
`
`Residence Information (Select One) (® US Residency
`Non US Residency
`Active US Military Service
`-
`
`
`
`Country of Residencd | Us
`State/Province | PA
`fudubon
`City
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mailing Address of Inventor:
`
`
`
`Address 1
`D707 Bald Eagle Circle
`
`
`Address 2
`City
`| Pudubon
`State/Province
`| PA
`
`Postal Code
`19403
`Countryi
`| us
`
`
`
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`
`
`Add
`
`
`
`Correspondence Information:
`
`
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`
`
`[] An Address is being provided for the correspondence Information of this application.
`
`
`
`Customer Number
`
`68249
`
`
`
`
`
`
`
`Email Address
`
`
`
`
`
` ZPATDCDOCKETING@COOLEY.COM
`
`| Remove Email
`|
`Add Email
`|
`
`
`
`
`Application Information:
`
`
`
`Title of the Invention
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`Attorney Docket Number| [SYPA-009/C04US
`Small Entity Status Claimed
`[X]
`
`Application Type
`Nonprovisional
`v
`
`
`
`Subject Matter
`
`Utility
`
`v
`
`Total Number of Drawing Sheets (if any)
`6
`Suggested Figure for Publication (if any)
`
`
`
`
`
`
`
`
`
`
`
`EFS Web 2.2.12
`
`0009
`
`0009
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`
`Application Data Sheet 37 CFR 1.76
`
`
`
`
`
` Application Number
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
`Filing By Reference:
`
`
`
`Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., “Domestic Benefit/National Stage Information” and “Foreign Priority Information”).
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country N
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Publication Information:
`
`[]
`
`Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`
`
`
`
`Req uest Not to Publish. | hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`
`
`Representative Information:
`
`
`
`all practitioners having a power of attorney in the application. Providing
`Representative information should be provided for
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`
`
`
`
`Please Select One:
`
`e
`
`Customer Number
`
`US Patent Practitioner
`
`(0
`
`Limited Recognition (37 CFR 11.9)
`
`
`
`
`
`K8249
`Customer Number
`
`
`
`
`
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the “Application Number” field blank.
`
`
`
`Prior Application Status | Pending
`-
`Remove
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`
`
`2015-09-04
`14845644
`[Continuation of
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`
`
`EFS Web 2.2.12
`
`0010
`
`0010
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1.76
` Application Number
`
`Attorney Docket Number
`
`SYPA-009/C04US
`
`
`
`
`
`Title of Invention
`
`FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
`
`
`Prior Application Status
`
`pbandoned
`
`.
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
`
`14845644
`
`Continuation of
`
`Prior Application Status | Pending
`
`14661299
`
`2015-03-18
`
`+]
`
`v
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`14661299
`
`Continuation of
`
`«|
`
`13421769
`012-03-15
`
`
`
`
`Prior Application Status | [Expired
`v
`Remove
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`
`
`
`13421769
`
`Continuation in part of
`
`~|
`
`PCTUS2011051805
`
`2011-09-15
`
`
`
`
`Prior Application Status |
`[Expired
`-
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
`
`
`
`
`
`
`
`PCTUS2011051805
`Claims benefit of provisional
`+]
`61392186
`2010-10-12
`
`
`Prior Application Status | Expired
`v
`Remove
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`PCTUS2011051805
`Claims benefit of provisional
`+]
`61387636
`2010-09-29
`
`
`Prior Application Status | [Expired
`-
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`PCTUS2011051805
`Claims benefit of provisional
`+]
`61383156
`2010-09-15
`
`
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`Aad
`by selecting the Add button.
`
`Foreign Priority Information:
`
`
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application
`
`that is eligible for retrieval under the priority document exchange program (PDX) the information will be used by the Office to
`
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate
`
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`
`
`
`
`
`
`EFS Web 2.2.12
`
`0011
`
`0011
`
`

`

`
`
`
`
`
`
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`
`
`
`
`
`
`
`
`PTO/AIA/4 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`
`Application Data Sheet 37 CFR 1.76
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
` Application Number
`
`
`
`Application Number
`
`Country’
`
`Filing Date (YYYY-MM-DD)
`
`Access Code! (if applicable)
`
`Remove
`
`
`
`
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`[]
`
` This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AlA.
`
`
`
`
`
`
`
`EFS Web 2.2.12
`
`0012
`
`0012
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`}
`}
`Application Data Sheet 37 CFR 1.76
`
`Application Number
`
`
`
`
`
`Title of Invention
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph B in subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the
`
`undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office
`
`(JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People’s Republic of
`China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office
`participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)
`(1).
`
`B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked,
`
`the undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search
`
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO’s Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
` 2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`
`
`IX]
`
`IX]
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant
`application.
`
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the
`application in accordance with 37 CFR 1.14.
`
`EFS Web 2.2.12
`
`0013
`
`0013
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
`
`
`Applicant Information:
`
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`
`Applicant
`
`{1
`
`
`
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`
`
`Assignee
`
`Legal Representative under 35 U.S.C. 117
`
`Joint Inventor
`
`
`Person to whom the inventor is obligated to assign.
`
`
`
`®
`
`
` If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`Person who shows sufficient proprietary interest
`
`
`
`-1
`
`
`
`
`Name of the Deceased or Legally Incapacitated Inventor:
`
`
`
`
`
`
`
`
`
`If the Applicant is an Organization check here.
`
`X
`
`
`
`
`
` Organization Name | byNFRGY PHARMACEUTICALS, INC.
`
`
`Mailing Address Information For Applicant:
`
`
`
`
`
`Address 1
`
`20 Lexington Avenue
`
`Address 2
`
`Suite 2012
`
`
`
`
`
`City
`
`New York
`
`State/Province
`
`NY
`
`Country | Us
`
`Phone Number
`
`Postal Code
`
`Fax Number
`
`10170
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Email Address
`
`
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`
`
`Assignee Information including Non-Applicant Assignee Information:
`
` Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title
`37 of CFR to have an assignment recorded by the Office.
`
`
`
`
`
`
`
`EFS Web 2.2.12
`
`0014
`
`0014
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number | SYPA-009/C04US
`Application Data Sheet 37 CFR 1.76
`
`
`Application Number
`
`Title of Invention
`
`| FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
`
`
`
`
`
`
`Assignee
`
`(1
`
`
`
`
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication. An assignee-applicant identified in the "Applicant Information” section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`[]
`
`
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`
`
`
`
`
`
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`
`
`
`
`
`
`
`
`Suffix
`
`
`
`
`
`
`
`
`
`
`
`
`Address 1
`
`
`Address 2
`City
`State/Province
`
`
`Country
`Postal Code
`
`
`Phone Number
`
`Fax Number
`
`
`
`
`
`
`Email Address
`
`
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`ad
`
`
`
`
`
`Signature:
`
`
`
`NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). However, if this Application
`Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in
`
`subsection 2 of the “Authorization or Opt-Out of Authorization to Permit Access” section, then this form must
`also be signed in accordance with 37 CFR 1.14(c).
`This Application Data Sheet must be signed by a patent practitioner if one or more of the applicants is a juristic
`
`entity (e.g., corporation or association). If the